(HealthDay News) — Low-dose aspirin can be used for primary cardiovascular prevention for patients at high cardiovascular risk, without increased bleeding risk, according to a review article published in the Journal of the American College of Cardiology.
Sigrun Halvorsen, MD, from Oslo University Hospital Ulleval in Norway, and colleagues reviewed the evidence for and against aspirin use in primary cardiovascular (CV) prevention.
Based on the currently available evidence of CV benefits and potentially increased bleeding risk, the researchers recommend that a pragmatic approach should guide low-dose aspirin use in primary CV prevention.
Aspirin is recommended for patients at high CV risk, defined as two or more major CV events projected per 100 person-years, who are not at increased risk of bleeding.
“We recommend that aspirin use in the primary prevention of acute myocardial infarction and other atherothrombotic cardiovascular events in subjects of both sexes is guided by an assessment of the underlying cardiovascular risk,” the researchers wrote.
Several authors disclosed financial ties to the pharmaceutical industry.